HEALTH

Biotech Firms Reach Settlement: Xoma Corp. and Centocor Inc. have agreed to settle all outstanding litigation and disputes surrounding their competing sepsis drugs, ending more than two years of wrangling. The biotechnology rivals also agreed to forgo future claims regarding each other’s patents and patent applications for anti-endotoxin monoclonal antibodies, which treat life-threatening blood infections contracted in hospitals. Centocor agreed to pay Xoma unspecified royalties for U.S. sales of its HA-1A sepsis drug, which is sold as Centoxin overseas.